



**EMMESSAR BIOTECH & NUTRITION LTD**

**UNAUDITED FINANCIAL RESULTS AS ON 30TH SEPTEMBER 2015**

(Rs. In Lakhs)

Particulars	Current	Preceding	Corresponding	Half Year	Corresponding	Previous Year
	Qtr Ended 30.09.2015 Unaudited	Qtr Ended 30.06.2015 Unaudited	Qtr Ended 30.09.2014 Unaudited	Ended 30.09.2015 Unaudited	Half Year Ended 30.09.2014 Unaudited	Ended 31.03.2015 Audited
01) Sales / Income from Operations (Gross)	21.81	113.86	41.79	135.67	67.65	228.12
Less: Excise Duty	0.24	5.05	3.28	5.29	3.62	9.09
(a) Net Sales / Income from operations	21.57	108.81	38.51	130.38	64.03	219.03
(b) Other Income	-	-	-	-	-	-
<b>Total Income</b>	<b>21.57</b>	<b>108.81</b>	<b>38.51</b>	<b>130.38</b>	<b>64.03</b>	<b>219.03</b>
02) Expenditure						
(a) (Increase) / Decrease in stock in trade	(3.55)	(13.04)	(26.30)	(16.59)	(38.55)	(26.95)
(b) Consumption of Raw materials	8.09	43.16	26.96	51.25	44.59	102.27
(c) Purchase of Traded goods	-	5.48	-	5.48	-	-
(d) Employee Cost	7.58	7.69	5.99	15.27	11.95	28.42
(e) Depreciation	0.37	0.37	1.71	0.74	3.42	6.87
(f) Other Expenditure	12.13	51.11	38.96	63.24	60.88	129.88
<b>Total Expenditure (a to f)</b>	<b>24.62</b>	<b>94.77</b>	<b>47.32</b>	<b>119.39</b>	<b>82.29</b>	<b>240.49</b>
03) Profit from Operations before Other Income Interest & Exceptional items (1 - 2)	(3.05)	14.04	(8.81)	10.99	(18.26)	(21.46)
04) Other Income	0.33	10.02	1.66	10.35	4.58	5.73
05) Profit before Interest and Exceptional Items (3 + 4)	(2.72)	24.06	(7.15)	21.34	(13.68)	(15.73)
06) Interest	-	-	-	-	-	-
07) Profit after Interest but before Exceptional Items (5 - 6)	(2.72)	24.06	(7.15)	21.34	(13.68)	(15.73)
08) Exceptional Items	-	-	-	-	-	-
09) Profit / (-) Loss from Ordinary Activities Before Taxation (7 + 8)	(2.72)	24.06	(7.15)	21.34	(13.68)	(15.73)
10) Tax Expense (Deferred tax)	-	-	-	-	-	(3.94)
11) Net Profit / (Loss) from Ordinary Activities after Taxation (9 - 10)	(2.72)	24.06	(7.15)	21.34	(13.68)	(11.79)
12) Extraordinary Item (net of tax expense)	(2.82)	95.00	-	92.18	-	-
13) Net Profit / Loss for the period (11-12)	0.10	(70.94)	(7.15)	(70.84)	(13.68)	(11.79)
14) Paid-up Equity Share Capital (Face Value of the share)	499.61	499.61	499.61	499.61	499.61	499.61
15) Reserves excluding Revaluation Reserve as per Balance Sheet of previous accounting year	10.00	10.00	10.00	10.00	10.00	10.00
16) Earning per Shares	0.00	(1.42)	(0.14)	(1.42)	(0.27)	(0.24)
a) Basic & diluted EPS before Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)						
b) Basic & diluted EPS after Extraordinary items for the period, for the year to date & for the previous year (not to be annulised)						
<b>PART II</b>						
<b>A. PARTICULARS OF SHAREHOLDINGS</b>						
1) Public Shareholding						
- No. of Shares	2074356	2106676	2183781	2074356	2340026	2302713
- Percentage of Shareholding	41.52	42.17	43.71	41.52	46.84	46.09
2) Promoters & Promoters Group Shareholding						
a) Pledged / Encumbered						
- No. of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (as % of the total Share Capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil
b) Non Encumbered						
- No. of Shares	2921744	2889424	2812319	2921744	2656074	2693387
- Percentage of Shares (as % of the total shareholding of the Promoter & Promoter Group)	100%	100%	100%	100%	100%	100%
- Percentage of Shares (as % of the total Share Capital of the Company)	58.48	57.83	56.29	58.48	53.16	53.91
<b>Three Months ended: 30.09.2015</b>						
<b>B. INVESTORS COMPLAINTS</b>						
Pending at the beginning of the quarter					Nil	
Received during the quarter					Nil	
Disposed of during the quarter					Nil	
Remaining unresolved at the end of the quarter.					Nil	
<ul style="list-style-type: none"> <li>* The above results were reviewed by the Audit Committee of the Board of Directors.</li> <li>* The Statutory Auditors have carried out a Limited Review of the results for the quarter ended September 30, 2015.</li> <li>* The above Un-Audited Results were taken on record at the meeting of the Board of Directors held on 6th November, 2015.</li> </ul>						
Mumbai				 By order of the Board MSR Ayyangar Managing Director		
6th November, 2015						

**EMMESSAR BIOTECH & NUTRITION LIMITED**

Quarter ended Segment wise Revenue Results and Capital Employed						
Particulars	[Rs. In Lakhs]					
	Current Qtr Ended 30.09.2015 Unaudited	Preceding Qtr Ended 30.06.2015 Unaudited	Corresponding Qtr Ended 30.09.2014 Unaudited	Half Year Ended 30.09.2015 Unaudited	Corresponding Half Year Ended 30.09.2014 Unaudited	Previous Year Ended 31.03.2015 Audited
<b>1. Segment Revenue</b> (Net Sales / Income)						
a. Healthcare	19.32	20.79	11.51	40.11	18.85	44.82
b. Fine Chemicals	2.25	88.02	27.00	90.27	45.18	174.20
c. Others	0.33	10.02	1.66	10.35	4.58	5.48
<b>Total:</b>	<b>21.90</b>	<b>118.83</b>	<b>40.17</b>	<b>140.73</b>	<b>68.61</b>	<b>224.50</b>
Less: Inter Segment Revenue	-	-	-	-	-	-
<b>Net Sales / Income from Operations</b>	<b>21.90</b>	<b>118.83</b>	<b>40.17</b>	<b>140.73</b>	<b>68.61</b>	<b>224.50</b>
<b>2. Segment Results (Profit / Loss)</b> before Tax and Interest						
a. Healthcare	14.84	12.48	5.60	27.32	9.58	26.30
b. Fine Chemicals	(0.37)	21.75	2.81	21.38	4.93	26.10
c. Others	0.33	10.02	1.66	10.35	4.58	5.48
<b>Total:</b>	<b>14.80</b>	<b>44.25</b>	<b>10.07</b>	<b>59.05</b>	<b>19.09</b>	<b>57.88</b>
Less:						
Interest	-	-	-	-	-	-
Other Unallocable Expenditure net off Unallocable Income	14.70	115.19	17.22	129.89	32.77	73.61
<b>Total Profit before Tax</b>	<b>0.10</b>	<b>(70.94)</b>	<b>(7.15)</b>	<b>(70.84)</b>	<b>(13.68)</b>	<b>(15.73)</b>
<b>3. Capital Employed</b> (Segment Assets - Segment Liabilities)						
a. Healthcare	19.51	4.91	16.49	19.51	16.49	13.41
b. Fine Chemicals	39.76	79.45	12.66	39.76	12.66	28.38
c. Others	(56.96)	(79.14)	(40.06)	(56.96)	(40.06)	(37.51)
<b>Total:</b>	<b>2.31</b>	<b>5.22</b>	<b>(10.91)</b>	<b>2.31</b>	<b>(10.91)</b>	<b>4.28</b>

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 6th November, 2015.

Mumbai  
6th November, 2015

By order of the Board  
MSR Ayyangar  
Managing Director



<b>EMMESSAR BIOTECH &amp; NUTRITION LTD</b>			
<b>Statements of Assets &amp; Liabilities</b>			
<b>(Rs. In Lakhs)</b>			
	Particulars	As at 30.09.2015	As at 31.03.2015
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>SHAREHOLDER'S FUNDS:</b>		
	(a) Share Capital	499.61	499.61
	(b) Reserves & Surplus	(433.01)	(362.17)
	<b>Sub-total Shareholder's funds</b>	<b>66.60</b>	<b>137.44</b>
<b>2</b>	<b>Non-current Liabilities</b>		
	(a) Long-term borrowings	9.97	4.79
	(b) Deferred tax liabilities (net)	10.04	10.04
	<b>Sub-total Non-current liabilities</b>	<b>20.01</b>	<b>14.83</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Trade payables	17.90	30.90
	(b) Other current Liabilities	73.34	54.40
	(c) Short-term provisions	0.86	4.37
	<b>Sub-total Current Liabilities</b>	<b>92.10</b>	<b>89.67</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>178.71</b>	<b>241.94</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Fixed Assets	73.75	142.47
	(b) Non-current investments	0.57	0.57
	(c) Long-term loans and advances	13.86	11.90
	<b>Sub-total Non-current Assets</b>	<b>88.18</b>	<b>154.94</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	73.18	68.77
	(b) Trade Receivables	4.25	3.93
	(c) Cash & Cash equivalents	2.77	2.40
	(d) Short-term loans and advances	10.33	11.90
	<b>Sub-total Current Assets</b>	<b>90.53</b>	<b>87.00</b>
	<b>TOTAL ASSETS</b>	<b>178.71</b>	<b>241.94</b>

*[Handwritten Signature]*



Tel. : 2200 4465, 2206 7440  
Fax : 91-22-2200 0649  
E-mail : mumbai@vsa.co.in  
Website : www.vsa.co.in

**V. Sankar Aiyar & Co.**  
CHARTERED ACCOUNTANTS  
2-C, Court Chambers  
35, New Marine Lines  
Mumbai - 400 020

**LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL RESULTS  
FOR THE HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER 2015**

The Board of Directors  
Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Emmessar Biotech & Nutrition Limited, for the half year ended 30th September 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors at its Meeting held on 6<sup>th</sup> November 2015. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above for the half year ended 30th September 2015, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements including the manner in which it is to be disclosed, or that it contains any material misstatements.

**For V. Sankar Aiyar & Co.  
Chartered Accountants  
Firm Regn. No.109208W**



**(V. Mohan)  
Partner**

**Membership No. 17748**

Place: Mumbai  
Date : November 6, 2015